A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.
A color vision test shows good correlation with cone and cone-rod dystrophy biomarkers and may offer a cost-effective replacement for ERG.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback